Completed PHASE1 INTERVENTIONAL NCT00003028

MEN-10755 in Treating Adults With Recurrent or Refractory Solid Tumors

Phase I Study to Determine the Safety of MEN-10755 (BMS-195615) in Patients With a Solid Tumor on a Short I.V. Infusion Given Once Every 3 Weeks

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Unspecified Adult Solid Tumor, Protocol Specific

Interventions sabarubicin

Updated 6 times since 2017 Last updated: Jun 29, 2012 Started: Apr 30, 1997

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Unspecified Adult Solid Tumor, Protocol Specific, this trial is completed. The trial is conducted by European Organisation for Research and Treatment of Cancer - EORTC and has accumulated 6 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Organisation for Research and Treatment of Cancer - EORTC

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Aviano, Italy , Basel, Switzerland , Bellinzona, Switzerland , Bern, Switzerland , Bordeaux, France , Brussels, Belgium , Clermont-Ferrand, France , Copenhagen, Denmark , Dijon, France and 36 more locations